By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Incyte Corporation 

1801 Augustine Cut-Off

Wilmington  Delaware  19803  U.S.A.
Phone: 1-855-446-2983 Fax: n/a


SEARCH JOBS

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. Our first commercial product, Jakafi®, is approved in the U.S. for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.

Science and Innovation

At Incyte, science drives success. Our world-class expertise, investment in sound and precise science, and our rigorous pursuit of R&D drive our efforts to identify new molecules with the potential to improve the lives of patients, make a difference in health care, and build sustainable value for all our stakeholders.

Patients

We are committed to positively impacting the lives of patients with cancer and other diseases. Our clinical research is held to the highest standards of scientific and ethical rigor and we strive to implement programs and initiatives to remove any possible barriers to access for our medicines.

Compliance and Transparency

We aim to make a difference—for patients, medical professionals, organizations, the broader healthcare community and all our global stakeholders. To achieve these goals, we are committed to conducting business ethically. We hold ourselves accountable to the highest standards to ensure that all of our interactions are conducted appropriately. We regularly review and amend our practices according to our own standards, as well as the standards required of us by the communities in which we live and work.

Our Global Community

We exist to improve the lives of people facing life-altering and life-threatening diseases like cancer, and actively support various local and global initiatives that are health-related or benefit the communities in which we live and work.

We strive to comply with all laws and regulations that govern environmental, health and safety matters and to sustainable business practices.


Key Statistics


Email:
Ownership: Public

Web Site: Incyte
Employees:
Symbol: INCY
 









Company News
Incyte (INCY) Announces First Patient Treated In ECHO-301 Phase 3 Study 6/23/2016 11:12:03 AM
FDA Grants Breakthrough Therapy Designation For Incyte (INCY)’s Ruxolitinib (Jakafi) In Acute Graft-Versus-Host Disease (GVHD) 6/23/2016 10:43:44 AM
FDA Bestows Incyte (INCY)'s Ruxolitinib with Breakthrough Tag for Graft-Versus-Host Disease 6/23/2016 6:13:26 AM
Looking at the Odds, Pfizer (PFE), Incyte (INCY) or Merck & Co. (MRK) Will Gobble Up Tiny Agenus (AGEN) 6/14/2016 6:50:00 AM
Incyte (INCY) Release: New Phase III Data Show Jakafi (Ruxolitinib) Is Superior To Best Available Therapy In Patients With Polycythemia Vera (PV) 6/10/2016 8:37:28 AM
ASCO2016: Incyte (INCY) Release: Five-Year Results From Phase III Study Of Jakafi (Ruxolitinib) Show Sustained Overall Survival Benefit In Patients With Myelofibrosis (MF) 6/6/2016 8:59:46 AM
Incyte (INCY) Announces The Launch Of The Incyte Charitable Giving Foundation 6/1/2016 12:41:38 PM
Incyte (INCY) And Moffitt Cancer Center Establish Multi-Year Oncology Research Alliance 6/1/2016 12:03:30 PM
Incyte (INCY) Highlights Jakafi (Ruxolitinib) And Capmatinib Abstracts To Be Presented At The 2016 ASCO And European Hematology Association Annual Meetings 5/19/2016 12:50:03 PM
Incyte (INCY) To Present At Upcoming Investor Conferences 5/18/2016 9:23:39 AM
12345678910...
//-->